KR102158134B1 - Antibacterial composition comprising an extract of schisandra chinesis - Google Patents
Antibacterial composition comprising an extract of schisandra chinesis Download PDFInfo
- Publication number
- KR102158134B1 KR102158134B1 KR1020170087066A KR20170087066A KR102158134B1 KR 102158134 B1 KR102158134 B1 KR 102158134B1 KR 1020170087066 A KR1020170087066 A KR 1020170087066A KR 20170087066 A KR20170087066 A KR 20170087066A KR 102158134 B1 KR102158134 B1 KR 102158134B1
- Authority
- KR
- South Korea
- Prior art keywords
- schisandra chinensis
- antibacterial
- extract
- chinensis extract
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000008422 Schisandra chinensis Nutrition 0.000 title claims abstract description 85
- 240000006079 Schisandra chinensis Species 0.000 title claims abstract description 83
- 239000000284 extract Substances 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000002537 cosmetic Substances 0.000 claims description 14
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001988 toxicity Effects 0.000 abstract description 7
- 231100000419 toxicity Toxicity 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 6
- 230000000845 anti-microbial effect Effects 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 17
- 238000000605 extraction Methods 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 241000186427 Cutibacterium acnes Species 0.000 description 5
- 108010059993 Vancomycin Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 5
- 229960003165 vancomycin Drugs 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000736075 Schisandra Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 2
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- -1 pregomoisin Natural products 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930185889 Epigomisin Natural products 0.000 description 1
- GWDFJIBHVSYXQL-SYTFOFBDSA-N Epigomisin O Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](O)[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 GWDFJIBHVSYXQL-SYTFOFBDSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- PLKFSXFJGNZAER-UHFFFAOYSA-N Tigloylgomisin O Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C(OC(=O)C(C)=CC)C(C)C(C)CC2=CC2=C1OCO2 PLKFSXFJGNZAER-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- PLKFSXFJGNZAER-XXDSNBTQSA-N [(8R,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (Z)-2-methylbut-2-enoate Chemical compound COc1cc2[C@H](OC(=O)C(\C)=C/C)[C@@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC PLKFSXFJGNZAER-XXDSNBTQSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B2/00—Preservation of foods or foodstuffs, in general
- A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
- A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
- A23B2/729—Organic compounds; Microorganisms; Enzymes
- A23B2/733—Compounds of undetermined constitution obtained from animals or plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 오미자 추출물을 유효성분으로 함유하는 항균용 조성물에 관한 것으로, 보다 상세하게는 천연원료인 오미자 추출물을 함유하여, 독성 및 부작용 없이 인체에 안전하게 사용할 수 있는 항균용 조성물로 응용할 수 있다.The present invention relates to an antibacterial composition containing Schisandra chinensis extract as an active ingredient, and more particularly, it contains Schisandra chinensis extract, a natural raw material, and can be applied as an antibacterial composition that can be safely used in the human body without toxicity and side effects.
Description
본 발명은 오미자 추출물을 유효성분으로 함유하는 항균용 조성물에 관한 것으로, 보다 상세하게는 천연원료인 오미자 추출물을 함유하여, 독성 및 부작용 없이 인체에 안전하게 사용할 수 있는 항균용 조성물을 제조하는 기술에 관한 것이다.
The present invention relates to an antimicrobial composition containing the Schisandra chinensis extract as an active ingredient, and more particularly, to a technology for preparing an antibacterial composition that can be safely used in the human body without toxicity and side effects by containing Schisandra chinensis extract, a natural raw material. will be.
병원성 미생물에 의한 직접 혹은 간접적인 피해는 경제, 환경, 의학적으로 많은 문제를 야기시키고 있다. 식품 산업에서의 식품 유통 과정 중의 부패로 인한 손실, 농산업에서의 농작물에 대한 과량의 화학 살충제의 사용으로 인한 인체의 유해성 및 환경오염, 항생제의 오남용으로 인한 항생제 내성 균주의 출현 등 사회 전반에서 많은 문제들을 야기시키고 있다.Direct or indirect damage caused by pathogenic microorganisms causes many economic, environmental and medical problems. Many problems in society, such as loss due to spoilage during the food distribution process in the food industry, harmfulness and environmental pollution to the human body due to the use of excessive chemical pesticides on agricultural products, and the emergence of antibiotic-resistant strains due to misuse of antibiotics. Are causing them.
인체 감염의 가장 흔한 원인균인 황색포도상구균의 마지막 치료제로 알려진 반코마이신에 고도의 내성을 보이는 포도상구균(vancomycin-resistant staphylococcus aureus, VRSA)이 2002년 미국 질병 통제국(Centers for Disease Control)에서 세계 최초로 보고됨으로써 소위 슈퍼 박테리아의 확산 가능성이 매우 높아지고 있다. 이는 반코마이신에 의해서만 치료가 되는 메치실린 내성 황색포도상구균(methicillin-resistant s. aureus, MRSA)이 1970년대부터 문제시된 이후 1988년 반코마이신에 내성을 보이는 장구균(vancomycin resistant enterococcus, VRE)이 유럽에서 처음으로 발견되었고, 1990년 후반에는 일본, 미국, 프랑스, 한국에서 보고된 반코마이신에 내성을 보이는 황색포도상구균(vancomycin intermediate-resistant s. aureus, VISA)이 발생하면서 범세계적인 위기로 떠오른 항생제 내성의 새로운 예로서 내성문제가 얼마나 심각한지를 보여 주고 있어 새로운 항생제 개발이 시급히 요구되고 있다(비특헌문헌 1; 비특허문헌 2).Vancomycin-resistant staphylococcus aureus (VRSA), which is highly resistant to vancomycin-resistant staphylococcus aureus, known as the last treatment for Staphylococcus aureus, the most common cause of human infection, was reported for the first time in the world by the Centers for Disease Control in 2002. As a result, the possibility of the spread of so-called super bacteria is very high. This is the first time in Europe where methicillin-resistant staphylococcus aureus (MRSA), which is treated only by vancomycin, was a problem since the 1970s. As a new example of antibiotic resistance, which emerged as a global crisis in the late 1990s, when vancomycin intermediate-resistant s. aureus (VISA), which is resistant to vancomycin, reported in Japan, the United States, France, and Korea occurred in the late 1990s. As it shows how serious the resistance problem is, the development of new antibiotics is urgently required (Non-Patent Document 1; Non-Patent Document 2).
현재 사용되고 있는 대부분의 항생제는 화학적인 합성을 통해 제조된 것으로서 고비용이 소요되며 부작용을 유발하는 등의 많은 한계를 가지고 있다. 따라서, 최근에는 천연물로부터 새로운 항균물질을 분리하고자 하는 연구가 활발하게 진행되고 있다. 천연물로부터 새로운 항균물질을 분리하기 위해서는 항균 스펙트럼이 광범위하고 장기간 투여하여도 부작용이 없이 안전하여야 한다는 점 등을 고려해야 한다.Most of the antibiotics currently used are manufactured through chemical synthesis, and are expensive and have many limitations, such as causing side effects. Therefore, in recent years, research to separate new antibacterial substances from natural products has been actively conducted. In order to separate new antimicrobial substances from natural products, it is necessary to consider the fact that the antimicrobial spectrum is broad and safe without side effects even after long-term administration.
최근에는 자연추출물에 대한 관심이 증가하면서 각종 식물에 대한 연구가 활발히 진행되고 있으며 항균 효과들이 알려지면서 많은 식물 추출물들이 항균성 조성물에 응용되고 있다.In recent years, as interest in natural extracts increases, research on various plants is being actively conducted, and as antibacterial effects are known, many plant extracts are applied to antibacterial compositions.
한편, 오미자(五味子, Schizandra chinensis Baillon.)는 낙엽 활엽 덩굴나무로 잎은 어긋나고 난형(卵形) 또는 도란형(倒卵形)이며 끝은 급히 뾰족하고 톱니가 있으며 뒷면 맥상에 다소 털이 있다. 꽃은 홍백색으로 6~7월에 피며 자웅이주이다. 과실은 식용으로 쓰이고 가지 끝에 이삭모양으로 늘어지며 8~9월에 붉게 익는다. 과실을 오미자(오매자), 북오미자(Schizandrae fructus)라 한다. 표고 200~1,600 m 지리산, 전북, 강원도가 주산지이며 충남, 충북을 제외한 전국에 야생하고, 지리적으로 일본, 사할린, 만주, 중국에 분포한다. 과실에는 시잔드롤(Schizandrol), 시잔드린(Schizandrin) A, B, C, 안겔로일고미신(angeloylgomisin) O, P, 에피고미신(epigomisin), 프레고모이신(pregomoisin), 데옥시시잔드린(Deoxyschizandrin) 등을 함유한다. 오미자는 오래 전부터 수렴, 자양, 강장, 진해약, 해주독, 목마름, 수렴고삽, 익기생진, 보신염심 등의 약효를 가져 생약원료로 한방에서 사용해오던 재료이며, 오미자주의 원료로 사용되어 온 것으로서 체내 섭취에 따른 인체 안정성이 이미 확인되어 있다.On the other hand, Omija (五味子, Schizandra chinensis Baillon.) is a deciduous broad-leaved vine, its leaves are alternated, ovate or obovate, and the tip is sharp and serrated, and there are some hairs on the veins on the back side. Flowers are red and white, bloom from June to July, and are hermaphrodite. Fruits are used for edible purposes, hang in a spike shape at the end of a branch, and ripen red in August-September. The fruits are called Schizandrae fructus and Schizandrae fructus. Altitude 200~1,600 m Jirisan, Jeonbuk, and Gangwon-do are the main production areas, wild throughout the country except Chungnam and Chungbuk, and geographically distributed in Japan, Sakhalin, Manchuria, and China. Fruits include: Schizandrol, Schizandrin A, B, C, angeloylgomisin O, P, epigomisin, pregomoisin, deoxyschizandrin. ), etc. Schisandra chinensis has long been used in herbal medicine as a raw material for herbal medicines with medicinal effects such as converging, nourishment, tonic, Jinhae medicine, Haejudok, thirst, sorghum gosap, ikgi saengjin, and bosin yeomsim. It has been used as a raw material for schisandra. The safety of the human body by ingestion has already been confirmed.
따라서, 본 발명자는 오미자 추출물을 제조할 수 있으면, 이를 이용하여 독성 및 부작용 없이 안전하게 사용할 수 있는 항균용 조성물로 응용할 수 있음에 착안하여 본 발명을 완성하기에 이르렀다.
Therefore, the present inventors have come to complete the present invention by conceiving that if the Schisandra chinensis extract can be prepared, it can be used as an antibacterial composition that can be safely used without toxicity and side effects.
본 발명은 상기와 같은 문제점을 고려하여 안출된 것으로, 본 발명의 목적은 천연원료인 오미자 추출물을 함유하여, 독성 및 부작용 없이 인체에 안전하게 사용할 수 있는 항균용 조성물을 제공하고자 하는 것이다.
The present invention has been conceived in consideration of the above problems, and an object of the present invention is to provide an antibacterial composition that can be safely used on the human body without toxicity and side effects by containing the extract of Schisandra chinensis, a natural raw material.
상기한 바와 같은 목적을 달성하기 위한 본 발명의 항균용 조성물은 오미자 추출물을 유효성분으로 함유할 수 있다.The antimicrobial composition of the present invention for achieving the above object may contain Schisandra chinensis extract as an active ingredient.
상기 오미자 추출물은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로 추출한 것일 수 있다.The Schisandra chinensis extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 오미자 추출물은 열수 추출물일 수 있다.The Schisandra chinensis extract may be a hot water extract.
상기 오미자는 오미자 과육일 수 있다.The Schisandra may be a pulp of Schisandra.
상기 오미자 추출물은 황색포도상구균(Staphylococcus aureus), 표피포도상구균(Staphylococcus epidermidis), 메치실린 내성 황색포도상구균(Methicillin-resistant S. aureus), 퀴놀론 내성 황색포도상구균(Quinolone-resistant S. aureus), 아키네토박테르 칼코아케티쿠스(Acinetobacter calcoaceticus), 마이크로코커스(Micrococcus luteus), 고초균(Bacillus subtilis) 및 스트렙토코커스 뮤탄스(Streptococcus mutans)로 이루어진 군에서 선택되는 1종 이상의 미생물에 대하여 항균활성을 나타낼 수 있다.The Schisandra chinensis extract is Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant S. aureus, quinolones-resistant Staphylococcus aureus, and Aki. It can exhibit antimicrobial activity against one or more microorganisms selected from the group consisting of Acinetobacter calcoaceticus, Micrococcus luteus, Bacillus subtilis, and Streptococcus mutans. have.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 항균용 약학 조성물은 오미자 추출물을 유효성분으로 함유할 수 있다.In addition, the antimicrobial pharmaceutical composition of the present invention for achieving the other object described above may contain Schisandra chinensis extract as an active ingredient.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 항균용 화장료 조성물은 오미자 추출물을 유효성분으로 함유할 수 있다.In addition, the antimicrobial cosmetic composition of the present invention for achieving the other objects described above may contain Schisandra chinensis extract as an active ingredient.
상기 화장료 조성물은 용액, 분말, 에멀션, 로션, 분사, 연고, 에어로졸, 크림 또는 거품의 형태일 수 있다. The cosmetic composition may be in the form of a solution, powder, emulsion, lotion, spray, ointment, aerosol, cream, or foam.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 항균용 식품 첨가제는 오미자 추출물을 유효성분으로 함유할 수 있다.In addition, the antimicrobial food additive of the present invention for achieving the other object described above may contain Schisandra chinensis extract as an active ingredient.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 항균용 사료 첨가제는 오미자 추출물을 유효성분으로 함유할 수 있다.In addition, the antimicrobial feed additive of the present invention for achieving the other object described above may contain Schisandra chinensis extract as an active ingredient.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 항균용 위생용품은 오미자 추출물을 유효성분으로 함유할 수 있다.
In addition, the antimicrobial hygiene product of the present invention for achieving the other object described above may contain the Schisandra chinensis extract as an active ingredient.
본 발명에 따르면, 천연원료인 오미자 추출물을 함유하여, 독성 및 부작용 없이 인체에 안전하게 사용할 수 있는 항균용 조성물을 제공할 수 있다.
According to the present invention, it is possible to provide an antibacterial composition that can be safely used in the human body without toxicity and side effects by containing the extract of Schisandra chinensis, a natural raw material.
도 1은 본 발명의 실시예 1 및 2로부터 제조된 오미자 추출물이 제조되는 공정을 나타낸 이미지이다.
도 2는 본 발명의 실시예 1 및 2로부터 제조된 오미자 추출물을 Disc diffusion assay에 의한 농도별 항균 활성을 측정한 결과 이미지이다.1 is an image showing a process in which the Schisandra chinensis extract prepared from Examples 1 and 2 of the present invention is prepared.
2 is an image of a result of measuring the antimicrobial activity of Schisandra chinensis extracts prepared from Examples 1 and 2 of the present invention by concentration by disc diffusion assay.
이하에서, 본 발명의 여러 측면 및 다양한 구현예에 대해 더욱 구체적으로 설명한다.Hereinafter, various aspects and various embodiments of the present invention will be described in more detail.
본 발명은 천연원료인 오미자 추출물을 함유하여, 독성 및 부작용 없이 인체에 안전하게 사용할 수 있는 항균용 조성물을 제조하는 기술에 관한 것이다.The present invention relates to a technology for preparing an antibacterial composition that can be safely used on the human body without toxicity and side effects by containing the extract of Schisandra chinensis, a natural raw material.
본 발명에서 "항균"은 세균에 저항하는 효능, 보다 상세하게는 약제나 생리활성물질에 의한 세균 및 진균의 생육저해작용을 의미한다.In the present invention, "antibacterial" refers to an effect against bacteria, and more specifically, an action of inhibiting the growth of bacteria and fungi by a drug or a physiologically active substance.
특히, 본 발명에 따른 오미자 추출물은 황색포도상구균(Staphylococcus aureus), 표피포도상구균(Staphylococcus epidermidis), 메치실린 내성 황색포도상구균(Methicillin-resistant S. aureus), 퀴놀론 내성 황색포도상구균(Quinolone-resistant S. aureus), 아키네토박테르 칼코아케티쿠스(Acinetobacter calcoaceticus), 마이크로코커스(Micrococcus luteus), 고초균(Bacillus subtilis) 및 스트렙토코커스 뮤탄스(Streptococcus mutans)로 이루어진 군에서 선택되는 1종 이상의 미생물에 대하여 항균활성을 나타내는 것이 바람직하나, 특별히 상기 종류의 균주에만 한정되는 것은 아니다.
In particular, the Schisandra chinensis extract according to the present invention includes Staphylococcus aureus, Staphylococcus epidermidis, Methicillin-resistant S. aureus, and Quinolone-resistant Staphylococcus aureus (Quinolone-resistant S. aureus), Acinetobacter calcoaceticus, Micrococcus luteus, Bacillus subtilis, and Streptococcus mutans against at least one microorganism selected from the group consisting of It is preferable to exhibit antimicrobial activity, but is not particularly limited to the above type of strain.
이하에서, 본 발명의 여러 측면 및 다양한 구현예에 대해 더욱 구체적으로 설명한다.Hereinafter, various aspects and various embodiments of the present invention will be described in more detail.
본 발명의 항균용 조성물은 오미자 추출물을 유효성분으로 함유할 수 있다.The antimicrobial composition of the present invention may contain Schisandra chinensis extract as an active ingredient.
상기 오미자 추출물은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로 추출한 것일 수 있다. 이때 상기 저급 알코올은 특별히 한정되는 것은 아니지만 20 내지 100 부피%의 메탄올, 에탄올, 프로판올 또는 부탄올일 수 있다.The Schisandra chinensis extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. At this time, the lower alcohol is not particularly limited, but may be 20 to 100% by volume of methanol, ethanol, propanol, or butanol.
본 발명에서는 추출용매로 물을 사용하여 열수 추출한 오미자 추출물을 사용하는 것이 바람직하고, 오미자 부위 중 과육을 사용하는 것이 바람직하다.In the present invention, it is preferable to use Schisandra chinensis extract extracted with hot water using water as an extraction solvent, and it is preferable to use the pulp of Schisandra chinensis.
상기 오미자 열수 추출물을 제조하기 위한 두 가지 방법을 하기와 같이 제시한다.Two methods for preparing the Schisandra chinensis hot water extract are presented as follows.
첫 번째 방법으로, 오미자를 증류수로 수세하고 건조하여 오미자 건조과육을 수득한다. 다음으로 상기 오미자 건조과육에 5 내지 15 배, 바람직하게는 6 내지 12 배, 더욱 바람직하게는 8 내지 10 배 중량의 정제수를 가하고, 30 내지 90 ℃, 바람직하게는 40 내지 80 ℃, 더욱 바람직하게는 50 내지 70 ℃ 에서, 1 내지 5 시간, 바람직하게는 2 내지 4 시간 동안 열수 추출하여 오미자 열수 추출물을 제조할 수 있다.In the first method, the dried Schisandra chinensis is obtained by washing with distilled water and drying it. Next, 5 to 15 times, preferably 6 to 12 times, more preferably 8 to 10 times the weight of purified water is added to the dried Schisandra chinensis flesh, and 30 to 90°C, preferably 40 to 80°C, more preferably Schisandra chinensis extract can be prepared by hot water extraction at 50 to 70° C. for 1 to 5 hours, preferably 2 to 4 hours.
두 번째 방법으로, 오미자를 증류수로 수세하고, 건조하여 오미자 건조과육을 수득한다. 다음으로 상기 오미자 건조과육을 분쇄한 오미자 분쇄물에 5 내지 15 배, 바람직하게는 6 내지 12 배, 더욱 바람직하게는 8 내지 10 배 중량의 정제수를 가하고, 30 내지 90 ℃, 바람직하게는 40 내지 80 ℃, 더욱 바람직하게는 50 내지 70 ℃ 에서, 바람직하게는 6 내지 12 시간, 바람직하게는 7 내지 9 시간 동안 열수 추출하여 오미자 열수 추출물을 제조할 수 있다.In the second method, the Schisandra chinensis is washed with distilled water and dried to obtain dried Schisandra chinensis. Next, 5 to 15 times, preferably 6 to 12 times, more preferably 8 to 10 times the weight of purified water is added to the pulverized Schisandra chinensis pulverized product, and 30 to 90°C, preferably 40 to Hot water extraction at 80° C., more preferably 50 to 70° C., preferably 6 to 12 hours, preferably 7 to 9 hours, can be performed to prepare a hot water extract of Schisandra chinensis.
상기 오미자 추출물은 제조된 상기 열수 추출물들을 각각 여과하고 농축하는 단계를 더욱 포함하여 제조될 수 있다.The Schisandra chinensis extract may be prepared further comprising filtering and concentrating each of the prepared hot water extracts.
상기 추출 시 추출용매와 오미자 건물의 중량비가 상기 범위를 벗어나는 경우에는 오미자 성분의 생리활성 효과가 저하될 수 있다.When the weight ratio between the extraction solvent and Schisandra chinensis during the extraction is out of the above range, the physiological activity effect of the Schisandra chinensis component may be lowered.
또한, 상기 추출온도 범위를 벗어날 경우에는 항균 효능이 현저히 저하될 수 있다.In addition, if the extraction temperature is out of range, antibacterial efficacy may be significantly reduced.
본 발명의 오미자 추출물은 0.001 내지 20 mg/㎖의 농도로 사용되는데, 농도가 상기 하한치 미만인 경우에는 항균 효능을 기대할 수 없으며, 상기 상한치 초과인 경우에는 독성을 유발할 수 있다.The Schisandra chinensis extract of the present invention is used in a concentration of 0.001 to 20 mg/ml. If the concentration is less than the lower limit, antibacterial efficacy cannot be expected, and if it exceeds the upper limit, toxicity may occur.
상기와 같이 제조된 오미자 추출물은 추출물 자체로 이용하거나, 사용이 편리하도록 분말화하여 이용할 수 있다. 상기 오미자 추출물을 분말화하는 방법은 추출물을 감압 농축하여 부피를 줄인 후 동결건조, 분무건조 및 열풍건조로 이루어진 군으로부터 선택되는 1종, 바람직하게는 동결건조하여 분말화한다.The Schisandra chinensis extract prepared as described above may be used as an extract itself, or may be powdered for convenient use. The method of powdering the Schisandra chinensis extract is to reduce the volume by concentrating the extract under reduced pressure, and then powdering the extract by lyophilization, spray drying, and hot air drying.
본 발명의 오미자 추출물을 유효성분으로 함유하는 항균용 조성물은 오미자 추출물을 약학적 조성물 총 중량을 기준으로 0.001 내지 20 중량%, 바람직하게는 0.01 내지 10 중량%로 포함한다.The antimicrobial composition containing the Schisandra chinensis extract of the present invention as an active ingredient comprises 0.001 to 20% by weight, preferably 0.01 to 10% by weight, based on the total weight of the pharmaceutical composition.
본 발명의 또 다른 특징에 따른 항균용 약학 조성물은 상기 본 발명에 따른 오미자 추출물을 유효성분으로 포함한다.The antibacterial pharmaceutical composition according to another feature of the present invention comprises the Schisandra chinensis extract according to the present invention as an active ingredient.
상기 약학 조성물의 투여 방법은 특별한 제한이 있는 것은 아니지만, 바람직하게는 동맥 또는 정맥 내로 투입하거나, 피하로, 직장으로, 비강으로, 임의의 다른 비경구로도 투입될 수 있으며, 더욱 바람직하게는 동맥 또는 정맥 내로 투입하거나 경구 투여하거나 또는 근육 세포에 직접 투입하는 것이 바람직하다.The method of administering the pharmaceutical composition is not particularly limited, but is preferably injected into an artery or vein, or subcutaneously, rectal, nasal, or any other parenteral administration, and more preferably, arterial or It is preferred to be administered intravenously, orally, or directly into muscle cells.
또한 상기 조성물로부터 선택되는 투여 수준은 화합물의 활성, 투여 경로, 치료되는 병태의 중증도 및 치료되는 환자의 병태 및 이전 병력에 따를 것이다. 그러나 원하는 치료 효과의 달성을 위해 요구되는 것보다 낮은 수준의 화합물의 용량에서 시작하여, 원하는 효과가 달성될 때까지 투여량을 서서히 증가시키는 것은 당업계의 지식 내에 있으며, 바람직한 투여량은 나이, 성별, 체형, 체중에 따라 결정될 수 있다. 상기 조성물은 약제학상 허용 가능한 제약 제제로 제제화 되기 전에 추가로 가공될 수 있으며, 바람직하게는 더 작은 입자들로 분쇄 또는 연마될 수 있다. 또한 상기 조성물은 병태 및 치료되는 환자에 따라 달라질 것이지만, 이는 비-독창적으로 결정할 수 있다. 바람직한 효과를 위해서, 본 발명의 오미자 추출물의 유효 용량은 1~2mg/kg이고, 바람직하게는 0.5~1mg/kg이며, 하루 1 내지 3회 투여될 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.In addition, the dosage level selected from the composition will depend on the activity of the compound, the route of administration, the severity of the condition being treated and the condition and previous medical history of the patient being treated. However, it is within the knowledge of the art to start with a dose of the compound at a lower level than required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved, and the preferred dosage is age, sex. , It can be determined according to body type and weight. The composition may be further processed prior to being formulated into a pharmaceutically acceptable pharmaceutical formulation, preferably pulverized or ground into smaller particles. Also, the composition will depend on the condition and the patient being treated, but this can be determined non-ingeniously. For a desirable effect, the effective dose of the Schisandra chinensis extract of the present invention is 1 to 2 mg/kg, preferably 0.5 to 1 mg/kg, and may be administered 1 to 3 times a day. The above dosage does not in any way limit the scope of the present invention.
상기 본 발명의 약학 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 산제, 과립제, 정제, 캅셀제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 외용제, 좌제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 사용할 수 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.
The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary knowledge in the art. Or it can be made by incorporating it into a multi-dose container. At this time, the dosage form can be used in any form suitable for pharmaceutical preparations, including oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations such as ointments and creams, suppositories and sterile injectable solutions, etc. , A dispersant or a stabilizer may additionally be included.
또한 상기 오미자 추출물은 항균 활성을 보이는 바실러스 서브틸리스(Bacillus subtilis), 스타필로코커스 에피더미디스(Staphylococcus epidermidis), 스타필로코커스 뮤탄스(Staphylococcus mutans), 프로피오니박테리움 아크네스(Propionibacterium acnes), 대장균(E. coli) D31, 대장균(E. coli) ML35p, 시겔라 플렉스네리(Shigella flexneri), 슈도모나스 에루지노사(Pseudomonas aeruginosa), 비브리오 파라헤몰리티쿠스(Vibrio parahaemolyticus) 또는 칸디다 알비칸스(Candida albicans)로부터 대표적으로 유발되는 질병인 식중독, 칸디다즘, 장티푸스, 콜레라 등의 질병을 예방 또는 치료하는 것이 가능하기 때문에, 상기 오미자 추출물을 유효성분으로 포함하여 상기 세균으로 인한 감염성 질환들의 예방 또는 치료용 약학 조성물로 활용될 수 있다.
In addition, the Schisandra chinensis extract is Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans, Propionibacterium acnes, E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa, Vibrio parahaemolyticus or Candida albicans (Candida) albicans), since it is possible to prevent or treat diseases such as food poisoning, candism, typhoid fever, cholera, etc., which are representative diseases from), the Schisandra chinensis extract is included as an active ingredient to prevent or treat infectious diseases caused by the bacteria. It can be used as a pharmaceutical composition.
또한 상기 오미자 추출물은 항균용 화장료 조성물의 유효성분으로 사용될 수 있다. 이때, 상기 화장료 조성물은 용액, 분말, 에멀션, 로션, 분사, 연고, 에어로졸, 크림 또는 거품의 형태일 수 있다. 또한, 본 발명의 화장료 조성물에 있어서는, 화장품 제제에 있어서 수용가능한 담체를 포함할 수 있다. 여기서 "화장품 제제에 있어서 수용가능한 담체"란 화장품 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 정도 이상의 독성, 불안정성 또는 자극성이 없는 것을 말한다.In addition, the Schisandra chinensis extract may be used as an active ingredient in an antibacterial cosmetic composition. At this time, the cosmetic composition may be in the form of a solution, powder, emulsion, lotion, spray, ointment, aerosol, cream, or foam. Further, in the cosmetic composition of the present invention, a carrier acceptable in a cosmetic formulation may be included. Herein, “acceptable carrier in cosmetic preparations” refers to a compound or composition that is already known and used that can be included in a cosmetic preparation, or is a compound or composition to be developed in the future. Say nothing.
상기 담체는 본 발명의 화장료 조성물에 그것의 전체 중량에 대하여 약 1중량% 내지 약 99.99중량%, 바람직하게는 조성물의 중량의 약 90중량% 내지 약 99.99중량%로 포함될 수 있다. 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선산란제, 자외선흡수제, 발색제, 향료 등이 예시될 수 있다. 상기 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선산란제, 자외선흡수제, 발색제, 향료로 사용될 수 있는 화합물 또는 조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당물질 또는 조성물을 선택하여 사용할 수 있다.The carrier may be included in the cosmetic composition of the present invention in an amount of about 1% to about 99.99% by weight, preferably about 90% to about 99.99% by weight, based on the total weight of the cosmetic composition. Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizing agents, viscosity modifiers, emulsions, stabilizers, ultraviolet scattering agents, ultraviolet absorbers, coloring agents, fragrances, and the like. Compounds or compositions that can be used as alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizing agents, viscosity modifiers, emulsions, stabilizers, ultraviolet scattering agents, ultraviolet absorbers, coloring agents, fragrances, etc. are already known in the art. Therefore, those skilled in the art can select and use an appropriate corresponding material or composition.
본 발명의 일 구현예로서, 본 발명에 따른 화장료 조성물은 상기 펩타이드 유사체 외에 글리세린, 부틸렌글리콜, 프로필렌글리콜, 폴리옥시에틸렌 경화피마자유, 에탄올, 트리에탄올아민 등을 포함할 수 있으며, 방부제, 향료, 착색료, 정제수 등을 필요에 따라 미량 포함할 수 있다.As an embodiment of the present invention, the cosmetic composition according to the present invention may contain glycerin, butylene glycol, propylene glycol, polyoxyethylene hydrogenated castor oil, ethanol, triethanolamine, etc., in addition to the peptide analogues, and preservatives, fragrances, Colorants, purified water, etc. may be included in trace amounts as needed.
본 발명에 있어서의 피부는 얼굴뿐만 아니라, 두피, 전신도 포함되는 개념으로, 이러한 두피에 적용될 수 있는 화장료 조성물로써, 샴푸, 린스, 트리트먼트, 발모제 등이 있고, 전신에 적용될 수 있는 바디클렌져 등의 용도로서 다양한 형태로 제조될 수 있다.
The skin in the present invention is a concept that includes not only the face, but also the scalp and the whole body, and as a cosmetic composition that can be applied to such scalp, there are shampoos, conditioners, treatments, hair growth agents, etc., and a body cleanser that can be applied to the whole body. It can be manufactured in various forms for use.
또한 상기 오미자 추출물은 항균용 식품 첨가제 또는 사료첨가제의 유효성분으로 사용될 수 있다.In addition, the Schisandra chinensis extract may be used as an active ingredient of an antibacterial food additive or a feed additive.
본 발명의 구체적인 실시예에서, 본 발명에 따른 오미자 추출물은 그람 음성 및 그람 양성균뿐만 아니라 진균에 대해서도 우수한 항균 활성을 가지고, 세포독성이 없어서 항균용 식품첨가제 또는 사료첨가제로 유용하게 이용될 수 있다.In a specific embodiment of the present invention, the Schisandra chinensis extract according to the present invention has excellent antimicrobial activity against not only Gram-negative and Gram-positive bacteria, but also fungi, and has no cytotoxicity, so it can be usefully used as an antibacterial food additive or feed additive.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스켓, 떡, 쵸코렛, 캔디류, 스넥류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다. 본 발명의 오미자 추출물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 중의 상기 오미자 추출물의 양은 전체 식품 중량의 0.1 내지 20중량%로 가할 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에, 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.
There is no particular limitation on the type of the food. Examples of foods to which the above substances can be added include drinks, meat, sausages, bread, biscuits, rice cakes, chocolates, candies, snacks, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, There are alcoholic beverages and vitamin complexes, and all health functional foods in the usual sense are included. The Schisandra chinensis extract of the present invention may be added to food as it is or may be used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (for prevention or improvement). In general, the amount of the Schisandra chinensis extract in the food may be added in an amount of 0.1 to 20% by weight of the total food weight. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be below the above range, and there is no problem in terms of safety, so the active ingredient may be used in an amount above the above range. .
또한 상기 오미자 추출물은 물티슈, 손 소독제, 구강청정제, 구강소독제, 치약첨가제와 같은 위생용품의 유효성분으로 유용하게 사용될 수 있다.
In addition, the Schisandra chinensis extract can be usefully used as an active ingredient in hygiene products such as wet tissues, hand sanitizers, mouthwashes, mouth disinfectants, and toothpaste additives.
이하 본 발명을 바람직한 실시예를 참고로 하여 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to preferred embodiments so that those of ordinary skill in the art can easily implement the present invention. However, the present invention may be implemented in various different forms and is not limited to the embodiments described herein.
<참조예><Reference example>
참조예 1: 균주의 배양Reference Example 1: Culture of strain
P.acnes는 GAM ("Nissui" Gifu anearobic medium) 배지를 사용하였으며 균을 배양배지에 접종한 후 anaerobic jar에 밀봉하여 37 ℃에서 48 시간 동안 혐기 배양 하였다. For P.acnes, GAM ("Nissui" Gifu anearobic medium) medium was used, and the bacteria were inoculated in a culture medium, sealed in an anaerobic jar, and anaerobic cultured at 37°C for 48 hours.
S.aureus 및 S.epidermidis는 NB (DifdoTM Nutrient Broth) 배지를 사용하였으며 균을 접종한 뒤 37 ℃에서 24 시간 동안 배양하여 사용하였다.
S.aureus and S.epidermidis was used as an NB (Nutrient Broth Difdo TM) medium was used to culture at 37 ℃ after inoculation with the bacteria for 24 hours.
<실시예><Example>
실시예 1: 미분쇄 오미자 과육 열수 추출물의 제조Example 1: Preparation of finely ground Schisandra chinensis pulp hot water extract
오미자를 증류수로 수세하고 건조한 오미자 과육 155 g에 9 배 중량의 정제수를 혼합하고 60 ℃ 및 상압 조건에서 3 시간 동안 추출하고, 추출물을 필터링한 후 감압여과하여 오미자 추출물 39.868 g을 수득하였다.
Schisandra chinensis was washed with distilled water, 9 times the weight of purified water was mixed with 155 g of dried Schisandra chinensis pulp, extracted for 3 hours at 60° C. and under normal pressure, and filtered under reduced pressure to obtain 39.868 g of Schisandra chinensis extract.
실시예 2: 분쇄 오미자 과육 열수 추출물의 제조Example 2: Preparation of hot water extract of crushed Schisandra chinensis
오미자를 증류수로 수세하고 건조한 오미자 과육을 분쇄하여, 분쇄 오미자 과육 155 g에 9 배 중량의 정제수를 혼합하고 60 ℃ 및 상압 조건에서 8 시간 동안 추출하고, 추출물을 필터링한 후 감압여과하여 오미자 추출물 48.055 g을 수득하였다.
Schisandra chinensis was washed with distilled water and dried Schisandra chinensis pulp was pulverized, 9 times the weight of purified water was mixed with 155 g of crushed Schisandra chinensis pulp, extracted for 8 hours at 60°C and under normal pressure conditions, filtered the extract, and filtered under reduced pressure to extract Schisandra chinensis 48.055 g was obtained.
하기 표 1에는 실시예 1에서 1 시간 및 3 시간 추출한 오미자 추출물 및 실시예 2에서 3 시간 및 8 시간 동안 추출한 오미자 추출물에 대하여 추출효율(%)을 비교한 표이다.Table 1 is a table comparing the extraction efficiency (%) with respect to the Schisandra chinensis extract extracted for 1 hour and 3 hours in Example 1 and the Schisandra chinensis extract extracted for 3 hours and 8 hours in Example 2.
하기 표 1을 참조하면, 추출시간이 증가할 수록 추출효율이 증가하는 것을 확인할 수 있다.
Referring to Table 1 below, it can be seen that as the extraction time increases, the extraction efficiency increases.
<< 실험예Experimental example >>
실험예 1: Disc diffusion assay에 의한 농도별 항균 활성 측정Experimental Example 1: Measurement of antimicrobial activity by concentration by disc diffusion assay
상기 실시예 1 및 2로부터 제조된 오미자 추출물들에 대한 항균활성은 시험 균주를 대상으로 Disc diffusion assay 방법으로 측정하였다. 추출물의 농도는 각각 200 mg/ml, 100 mg/ml, 50 mg/ml, 20 mg/ml 및 10 mg/ml로 멸균 증류수에 희석하여 121.0 ℃에 15 분 고온 고압 멸균하여 사용하였고, 평판배지에 배양된 각각의 균주를 멸균된 면봉을 이용하여 닦아낸 후 액체배지로 옮겨 현탁하여 50 ul씩 도말하여 준비하였다. paper disc(diamerter 8mm, Roshi kaisha.Ltd., Tokyo, Japan)를 균주를 도말한 평판배지위에 밀착시킨 후에 시료를 disc당 4 mg, 2 mg, 1 mg, 0.4 mg 및 0.2 mg이 되도록 paper disc에 천천히 흡수시킨 후 P.acnes는 37 ℃인큐베이터에 7 2시간 혐기 배양 후 생성된 저해환(clear zone, mm)을 측정하였고, S.epidermidis 및 S.aureus는 37 ℃ 인큐베이터에 48 시간 배양 후 disc 주변에 생성된 저해환(clear zone, mm)을 측정하여 항균 활성을 비교하였다. 대조군으로 멸균 증류수를 사용하였다.
The antimicrobial activity of the Schisandra chinensis extracts prepared from Examples 1 and 2 was measured by the Disc diffusion assay method for the test strain. The concentration of the extract was 200 mg/ml, 100 mg/ml, 50 mg/ml, 20 mg/ml, and 10 mg/ml, respectively, diluted in sterilized distilled water and sterilized at 121.0° C. for 15 minutes at high temperature and pressure, and used on a plate medium. Each cultured strain was wiped with a sterilized cotton swab, transferred to a liquid medium, suspended, and smeared 50 ul to prepare. After attaching a paper disc (diamerter 8mm, Roshi kaisha.Ltd., Tokyo, Japan) to the plate medium coated with the strain, the sample is placed on a paper disc so that it is 4 mg, 2 mg, 1 mg, 0.4 mg and 0.2 mg per disc. After slowly absorbing P.acnes, the clear zone (mm) generated after 7 2 hours of anaerobic incubation in a 37°C incubator was measured, and S.epidermidis and S.aureus were incubated in a 37°C incubator for 48 hours and then around the disc. Antimicrobial activity was compared by measuring the inhibitory ring (clear zone, mm) generated in. Sterile distilled water was used as a control.
도 2는 본 발명의 실시예 1 및 2로부터 제조된 오미자 열수 추출물을 Disc diffusion assay에 의한 농도별 항균 활성을 측정한 결과 이미지이고, 하기 표 1에는 본 발명의 실시예 1 및 2로부터 제조된 오미자 열수 추출물의 항균 활성 측정 결과를 수치적으로 나타내었다.2 is an image of a result of measuring the antimicrobial activity of Schisandra chinensis extracts prepared from Examples 1 and 2 of the present invention for each concentration by a disc diffusion assay, and Table 1 below shows Schisandra chinensis prepared from Examples 1 and 2 of the present invention. The results of measuring the antibacterial activity of the hot water extract are shown numerically.
도 2 및 표 1을 참조하면, 분쇄 및 미분쇄 오미자 과육 열수 추출물은 모두 S.aureus 및 S.epidermidi 균주에 대한 항균 효과가 있는 반면, P.acnes 균주에 대한 항균 효과는 없는 것을 확인할 수 있다.
Referring to Figure 2 and Table 1, it can be seen that both the pulverized and finely pulverized Schisandra chinensis extracts have antibacterial effects against S.aureus and S.epidermidi strains, whereas there is no antibacterial effect against P.acnes strains.
그러므로 본 발명에 따르면, 오미자 추출물을 제공할 수 있으며, 이를 이용하여 독성 및 부작용 없이 안전하게 사용할 수 있는 항균성 조성물로 응용할 수 있다.
Therefore, according to the present invention, it is possible to provide an extract of Schisandra chinensis, and by using it, it can be applied as an antibacterial composition that can be safely used without toxicity and side effects.
하기에는 본 발명의 오미자 추출물을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a formulation example of a composition containing the Schisandra chinensis extract of the present invention will be described, but the present invention is not intended to limit it, but is intended to be described in detail.
제제예 1. 산제의 제조Formulation Example 1. Preparation of powder
실시예 1 또는 2의 오미자 추출물 500 mg500 mg of Schisandra chinensis extract of Example 1 or 2
유당 100 mg100 mg lactose
탈크 10 mg10 mg of talc
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablet
실시예 1 또는 2의 오미자 추출물 300 mg300 mg of Schisandra chinensis extract of Example 1 or 2
옥수수전분 100 mg100 mg corn starch
유당 100 mg100 mg lactose
스테아린산 마그네슘 2 mg2 mg of magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet preparation method.
제제예 3. 캅셀제의 제조Formulation Example 3. Preparation of Capsule
실시예 1 또는 2의 오미자 추출물 200 mg200 mg of Schisandra chinensis extract of Example 1 or 2
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mg14.8 mg lactose
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
실시예 1 또는 2의 오미자 추출물 600 mg600 mg of Schisandra chinensis extract of Example 1 or 2
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mg2974 mg of sterile distilled water for injection
Na2HPO4,12H2O 26 mgNa 2 HPO 4, 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.
It is prepared with the above ingredients per ampoule according to a conventional injection preparation method.
제제예 5. 액제의 제조Formulation Example 5. Preparation of liquid formulation
실시예 1 또는 2의 오미자 추출물 4 g4 g of Schisandra chinensis extract of Example 1 or 2
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water appropriate amount
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
According to the usual preparation method of liquid formulations, add and dissolve each component in purified water, add an appropriate amount of lemon flavor, mix the above ingredients, add purified water, add purified water, adjust the total to 100 g, and fill in a brown bottle. It is sterilized to prepare a solution.
제제예 6. 과립제의 제조Formulation Example 6. Preparation of granules
실시예 1 또는 2의 오미자 추출물 1,000 mg1,000 mg of Schisandra chinensis extract of Example 1 or 2
비타민 혼합물 적량Vitamin mixture right amount
비타민 A 아세테이트 70 ㎍Vitamin A acetate 70 ㎍
비타민 E 1.0 mg1.0 mg of vitamin E
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mg0.5 mg of vitamin B6
비타민 B12 0.2 ㎍Vitamin B12 0.2 ㎍
비타민 C 10 mgVitamin C 10 mg
비오틴 10 ㎍Biotin 10 ㎍
니코틴산아미드 1.7 mg1.7 mg of nicotinic acid amide
엽산 50 ㎍Folic acid 50 ㎍
판토텐산 칼슘 0.5 mg0.5 mg of calcium pantothenate
무기질 혼합물 적량Suitable amount of inorganic mixture
황산제1철 1.75 mg1.75 mg ferrous sulfate
산화아연 0.82 mgZinc oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgDicalcium phosphate 55 mg
구연산칼륨 90 mg90 mg of potassium citrate
탄산칼슘 100 mg100 mg of calcium carbonate
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.
The composition ratio of the vitamin and mineral mixture is relatively suitable for granules, but it is possible to arbitrarily modify the mixing ratio. After mixing the above ingredients according to a conventional granule preparation method, granules And can be used to prepare a health functional food composition according to a conventional method.
제제예 7. 기능성 음료의 제조Formulation Example 7. Preparation of functional beverage
실시예 1 또는 2의 오미자 추출물 1,000 mg1,000 mg of Schisandra chinensis extract of Example 1 or 2
구연산 1,000 mg1,000 mg citric acid
올리고당 100 g100 g oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 mLTotal 900 mL with purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. After mixing the above ingredients according to the normal health drink manufacturing method, stirring and heating the mixture at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and stored in a refrigerator. It is used to prepare the functional beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
The composition ratio is composed of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences, such as the demand class, the country of demand, and the purpose of use.
Claims (11)
표피포도상구균(Staphylococcus epidermidis)에 대하여 항균활성을 갖는 것을 특징으로 하는, 항균용 조성물.It contains Schisandra chinensis extract as an active ingredient,
A composition for antibacterial, characterized in that it has antibacterial activity against Staphylococcus epidermidis.
상기 오미자 과육 추출물은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로 추출한 것을 특징으로 하는 항균용 조성물.The method of claim 1,
The Schisandra chinensis extract is an antibacterial composition, characterized in that the extract is extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 오미자 과육 추출물은 열수 추출물인 것을 특징으로 하는 항균용 조성물.The method of claim 1,
The Schisandra chinensis extract is an antibacterial composition, characterized in that the hot water extract.
표피포도상구균(Staphylococcus epidermidis)에 대하여 항균활성을 갖는 것 것을 특징으로 하는, 항균용 약학 조성물.It contains Schisandra chinensis extract as an active ingredient,
A pharmaceutical composition for antibacterial, characterized in that it has antibacterial activity against Staphylococcus epidermidis.
표피포도상구균(Staphylococcus epidermidis)에 대하여 항균활성을 갖는 것 것을 특징으로 하는, 항균용 화장료 조성물.It contains Schisandra chinensis extract as an active ingredient,
A cosmetic composition for antibacterial, characterized in that it has antibacterial activity against Staphylococcus epidermidis.
용액, 분말, 에멀션, 로션, 분사, 연고, 에어로졸, 크림 또는 거품의 형태인 것을 특징으로 하는 항균용 화장료 조성물.The method of claim 7,
Antibacterial cosmetic composition, characterized in that in the form of a solution, powder, emulsion, lotion, spray, ointment, aerosol, cream or foam.
표피포도상구균(Staphylococcus epidermidis)에 대하여 항균활성을 갖는 것을 특징으로 하는, 항균용 식품 첨가제.It contains Schisandra chinensis extract as an active ingredient,
A food additive for antibacterial, characterized in that it has antibacterial activity against Staphylococcus epidermidis.
표피포도상구균(Staphylococcus epidermidis)에 대하여 항균활성을 나타내는 것을 특징으로 하는, 항균용 사료 첨가제.It contains Schisandra chinensis extract as an active ingredient,
A feed additive for antibacterial, characterized in that it exhibits antibacterial activity against Staphylococcus epidermidis.
표피포도상구균(Staphylococcus epidermidis)에 대하여 항균활성을 나타내는 것을 특징으로 하는, 항균용 위생용품.It contains Schisandra chinensis extract as an active ingredient,
A hygiene product for antibacterial, characterized in that it exhibits antibacterial activity against Staphylococcus epidermidis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170087066A KR102158134B1 (en) | 2017-07-10 | 2017-07-10 | Antibacterial composition comprising an extract of schisandra chinesis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170087066A KR102158134B1 (en) | 2017-07-10 | 2017-07-10 | Antibacterial composition comprising an extract of schisandra chinesis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190006285A KR20190006285A (en) | 2019-01-18 |
KR102158134B1 true KR102158134B1 (en) | 2020-09-21 |
Family
ID=65323802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170087066A Active KR102158134B1 (en) | 2017-07-10 | 2017-07-10 | Antibacterial composition comprising an extract of schisandra chinesis |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102158134B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102235917B1 (en) * | 2019-09-19 | 2021-04-05 | 호서대학교 산학협력단 | Antibacterial composition containing natural material |
KR102591508B1 (en) * | 2021-02-23 | 2023-10-19 | 주식회사 가인화장품 | Anti-bacterial composition and cosmetic composition for improving of dandruff or acne comprising the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100394577B1 (en) * | 2000-11-16 | 2003-08-09 | 전라북도(농업기술원) | Crude extracts from Schizandra chinensis RUPRECHT seed and process for preparation thereof |
US20070128302A1 (en) * | 2003-11-07 | 2007-06-07 | Cognis France S.A. | Composition containing an extract of the fruit of schisandra chinensis and process for producing same |
KR100777833B1 (en) * | 2005-05-18 | 2007-11-28 | 원광대학교산학협력단 | Composition containing Schisandra chinensis extract having antimicrobial activity |
KR20100007529A (en) * | 2008-07-14 | 2010-01-22 | 조수동 | Antibacterial activity constituent of isolated benzoic acid derivatives from schizandra chinensis |
KR20100128833A (en) * | 2009-05-29 | 2010-12-08 | 금산군 산들약초영농조합법인 | Fresh Schisandra chinensis juice and its manufacturing method |
KR20140079610A (en) * | 2012-12-17 | 2014-06-27 | 대한민국(농촌진흥청장) | Antibacterial composition comprising an extract of Schizandrachinensis |
-
2017
- 2017-07-10 KR KR1020170087066A patent/KR102158134B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20190006285A (en) | 2019-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101841181B1 (en) | Toothpaste composition comprising herval extract | |
KR102356423B1 (en) | Composition Comprising Complex Strain with Anti-microbial, Skin Moisturizing, Anti-atopy, Skin Barrier, and Anti-wrinkle Property as Active Ingredient | |
KR20190079202A (en) | Fermentation method of lactic acid bacteria using citrus fruit and its use | |
KR101374267B1 (en) | Novel antibiotic peptide isolated from Nordotis discus discus and use thereof | |
KR102149973B1 (en) | Antimicrobial and Antifungal Composition Comprising Eugenol and Gallic Acid as Active Ingredient | |
KR102181371B1 (en) | Antimicrobial emulsion compositon comprising yuja seed oil and yuja juice as an active ingredient, use thereof and method preparing the same | |
KR20210014231A (en) | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract | |
KR101434465B1 (en) | Novel antibacterial and antifungal peptide isolated from Bacillus amyloliquefaciens EML-CAP3 and use thereof | |
KR102065185B1 (en) | Composition for Improving Skin Conditions with Improved Anti-Bacterial, Anti-inflammatory, Anti-wrinkling, and Skin Whitening Property | |
KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
KR101894807B1 (en) | Antimicrobial composition containing Rosa davurica extract as effective component | |
KR20220094308A (en) | Pharmaceutical composition for preventing or treating infectious symptoms by pathogenic microorganism comprising Cichorium intybus extract as an active ingredient | |
KR102172224B1 (en) | compositions containing fermented extract of Panax ginseng | |
KR20150087868A (en) | Novel antifungal peptide BA-1 isolated from Bacillus amyloliquefaciens EML-CAP-03 and use thereof | |
KR20230120619A (en) | Composition for improving skin conditions | |
KR20150133351A (en) | Antimicrobial composition comprising flavonol and antibiotic | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR20150064436A (en) | Composition for prevention and treatment of acne, containing spirits extract from Angelica as effective factor | |
KR102297957B1 (en) | A composition for improving, preventing and treating of acne and atopic dermatitis comprising black garlic extract | |
KR101429197B1 (en) | Antibacterial Composition Containing Anthriscus sylvestris Extract | |
KR102746020B1 (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Artemisia argyi extract | |
KR101359668B1 (en) | Antibacterial Composition Containing Sedum sarmentosum Extract | |
KR20210075916A (en) | Pharmaceutical composition for the prevention or treatment of obesity or metabolic syndrome induced from obesity containing enteroccocus faecalis as an active ingredient | |
KR20230001671A (en) | Anti-inflammatory and antibacterial composition comprising a Cedrela sinensis extract as an active ingredient | |
KR20180017974A (en) | Cosmetic composition for preventing or treating acne comprising combined herbal extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170710 |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180824 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20170710 Comment text: Patent Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191107 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200616 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200915 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20200916 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20230831 Start annual number: 4 End annual number: 4 |